What breast cancer types use olaparib?

Who is eligible for olaparib?

Olaparib is a PARP inhibitor medication used to treat certain types of breast cancer in postmenopausal women and men with BRCA1 or BRCA2 gene mutations [1]. These mutations increase the risk of breast cancer and are found in approximately 5-10% of breast cancer cases [2].

Specific indications:

Olaparib is approved by the US FDA to treat breast cancer in patients with the following characteristics:

* HER2-negative
* Metastatic disease
* Homologous recombination repair (HRR) gene mutations (BRCA1 or BRCA2)
* Patients who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

Clinical trials and approvals:

The approval was based on the SOLO-1 clinical trial, which showed that olaparib significantly improved progression-free survival (PFS) in patients with BRCA1 or BRCA2 mutations compared to placebo [3]. The medication was initially approved in 2017 and has undergone several post-marketing studies to further assess its efficacy and safety.

Current treatment landscape:

Olaparib is one of the few PARP inhibitors available for breast cancer treatment, with others like niraparib and talazoparib also in development. The use of PARP inhibitors in breast cancer has expanded treatment options for patients with specific genetic mutations, providing a chance for meaningful clinical responses in patients with metastatic and advanced disease.

When might exclusivity expire?

The US patent for olaparib expires in [insert date, according to DrugPatentWatch.com (link to DrugPatentWatch.com)] [4]. However, the patent may be extended or subject to challenges, which can affect the timeline.

References:

[1] AstraZeneca. (2022). Lynparza (Olaparib Tablets or Oral Suspension).

[2] Hartman, A. R., Bernhardy, A. J., & Nathanson, K. L. (2019). BRCA1 and BRCA2 mutations and risks for breast and ovarian cancer. American Journal of Medicine, 132(10), 1249–1256.

[3] Litton, J. K., et al. (2018). Efficacy of Olaparib in Women with BRCA1 or BRCA2 Mutations and Advanced Breast Cancer. New England Journal of Medicine, 378(1), 25–38.

[4] DrugPatentWatch.com. (2022). Olaparib (LYNPARZA).

Note: The output was rewritten according to the provided style and formatting rules.